147 related articles for article (PubMed ID: 29632709)
1. A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.
Zhang H; Lam L; Nagai Y; Zhu Z; Chen X; Ji MQ; Greene MI
Oncoimmunology; 2018; 7(4):e1300739. PubMed ID: 29632709
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
3. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
6. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.
Mason NJ; Gnanandarajah JS; Engiles JB; Gray F; Laughlin D; Gaurnier-Hausser A; Wallecha A; Huebner M; Paterson Y
Clin Cancer Res; 2016 Sep; 22(17):4380-90. PubMed ID: 26994144
[TBL] [Abstract][Full Text] [Related]
9. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor.
Rosenblum MG; Horn SA; Cheung LH
Int J Cancer; 2000 Oct; 88(2):267-73. PubMed ID: 11004679
[TBL] [Abstract][Full Text] [Related]
10. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
Daldrup-Link HE; Meier R; Rudelius M; Piontek G; Piert M; Metz S; Settles M; Uherek C; Wels W; Schlegel J; Rummeny EJ
Eur Radiol; 2005 Jan; 15(1):4-13. PubMed ID: 15616814
[TBL] [Abstract][Full Text] [Related]
11. A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Choi JH; Kim KH; Roh KH; Jung H; Lee A; Lee JY; Song JY; Park SJ; Kim I; Lee WS; Seo SK; Choi IW; Fu YX; Yea SS; Park S
Oncoimmunology; 2018; 7(5):e1421890. PubMed ID: 29721370
[TBL] [Abstract][Full Text] [Related]
12. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
[TBL] [Abstract][Full Text] [Related]
13. A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.
Glinka EM; Edelweiss EF; Sapozhnikov AM; Deyev SM
Gene; 2006 Jan; 366(1):97-103. PubMed ID: 16300908
[TBL] [Abstract][Full Text] [Related]
14. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
15. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
[TBL] [Abstract][Full Text] [Related]
16. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
17. DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice.
Wang Q; Cao W; Yang ZG; Zhao GF
Int J Clin Exp Med; 2015; 8(10):17565-77. PubMed ID: 26770347
[TBL] [Abstract][Full Text] [Related]
18. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
19. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.
Huang TH; Morrison SL
J Pharmacol Exp Ther; 2006 Mar; 316(3):983-91. PubMed ID: 16291729
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
